drugset / Trial / NCT01887288

Capecitabine With Digoxin for Metastatic Breast Cancer

NCT01887288

Phase 2 Terminated 16 enrolled Western Regional Medical Center
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the Growth Modulation Index (GMI) of the combination of metronomic capecitabine with oral digoxin in metastatic breast cancer

Timeline

Start
2013-04
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 650 mg/m2 Oral
Subject Digoxin Other / unclassified 0.25 mg Oral

Indications